These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 15041379

  • 1. Experience with therapeutic drug monitoring of cyclosporine.
    Abendroth D.
    Transplant Proc; 2004 Mar; 36(2 Suppl):426S-429S. PubMed ID: 15041379
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic drug monitoring of cyclosporine.
    Midtvedt K.
    Transplant Proc; 2004 Mar; 36(2 Suppl):430S-433S. PubMed ID: 15041380
    [Abstract] [Full Text] [Related]

  • 3. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 4. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
    Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W, Klepetko W.
    J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
    [Abstract] [Full Text] [Related]

  • 5. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
    Troncoso P, Ortiz AM, Jara A, Vilches S.
    Transplant Proc; 2009 Aug; 41(1):127-30. PubMed ID: 19249495
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients.
    Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K.
    Transplantation; 2008 Jan 27; 85(2):179-84. PubMed ID: 18212621
    [Abstract] [Full Text] [Related]

  • 8. A randomized, prospective, pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus tacrolimus trough concentration monitoring in de novo liver transplant recipients.
    Shenoy S, Hardinger KL, Crippin J, Korenblat K, Lisker-Melman M, Lowell JA, Chapman W.
    Liver Transpl; 2008 Feb 27; 14(2):173-80. PubMed ID: 18236391
    [Abstract] [Full Text] [Related]

  • 9. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
    Canadian Neoral Renal Transplantation Study Group.
    Transplantation; 2001 Sep 27; 72(6):1024-32. PubMed ID: 11579295
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic.
    Brunet M, Crespo M, Millán O, Serón D, Torregrosa V, Jiménez O, Moreso F, Martorell J, Grinyo JM, Oppenheimer F.
    Transplant Proc; 2007 Sep 27; 39(7):2160-2. PubMed ID: 17889124
    [Abstract] [Full Text] [Related]

  • 11. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 27; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The impact of cyclosporine on the development of immunosuppressive therapy: perspective from a transplant nephrologist involved with the development of C2.
    Cole E, Deshpande R.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):408S-413S. PubMed ID: 15041376
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Optimization of cyclosporine for liver transplantation.
    Lilly LB, Grant D.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):267S-270S. PubMed ID: 15041351
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic drug monitoring of cyclosporine: 20 years of progress.
    Kahan BD.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):378S-391S. PubMed ID: 15041372
    [Abstract] [Full Text] [Related]

  • 18. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun 27; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 19. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan 27; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 20. Preservation of renal function during maintenance therapy with cyclosporine.
    Serón D, Moreso F.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):257S-260S. PubMed ID: 15041349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.